small molecule

BEXAROTENE

BEXAROTENE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameBEXAROTENE
Active ingredientBEXAROTENE
Strength1%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.